Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Global X NASDAQ 100 Covered Call ETF trades at $18.15. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QYLD | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $18.52 |
52-Week Low | $16.87 | $16.46 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
QYLD trades at $18.14, up 0.33% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a high distribution yield, recently around 12%, supported by covered call strategies on the Nasdaq-100. Recent dividends include $0.18 and $0.19 per share, with the latest paid in July 2026. News highlights mixed views, with some analysts upgrading it for income potential while others warn of long-term underperformance versus the Nasdaq-100 index.
Outlook: QYLD appeals for high monthly income in sideways markets, but caps upside during rallies, posing a trade-off between yield and growth. Risks include erosion of net asset value over time and sensitivity to Nasdaq volatility. Investors should weigh income needs against potential capital appreciation limits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
